中国国产HPV疫苗价格与宫颈癌预防的经济回报:成本效果分析
该研究构建马尔可夫模型,从卫生系统角度评估中国9-14岁女孩接种国产Cecolin疫苗联合不同筛查策略的成本效果。疫苗两剂价格低于50美元时联合策略更优。
要点
- 每5年一次careHPV筛查联合疫苗接种是中国最具成本效果的宫颈癌预防策略。
- 疫苗两剂价格低于50美元时,联合策略在1倍人均GDP阈值下仍具成本效果。
核心结论
- 每5年一次careHPV筛查联合疫苗接种是中国宫颈癌预防最具成本效果的策略。
- 降低国产HPV疫苗价格是确保未来接种规划良好经济回报的必要条件。
研究设计与样本
- 在中国开展的成本效果分析,构建宫颈癌马尔可夫模型。
- 评估61种干预策略,包括不同筛查方法与疫苗接种的组合及单独接种,从卫生系统角度分析。
- 对10万9-14岁女孩队列进行终身模拟,并做单变量和概率敏感性分析。
主要发现
- 当疫苗两剂成本低于50美元时,联合策略比单独筛查策略更具成本效果,即使在1倍人均GDP的较低支付意愿下。
关键数值与推荐
- 疫苗两剂成本低于50美元时,联合策略在1倍人均GDP阈值下仍具成本效果。
临床怎么用
- 中国宫颈癌预防可优先考虑每5年一次careHPV筛查联合9-14岁女孩接种国产HPV疫苗。
- 推动国产HPV疫苗价格降至两剂50美元以下,以提升联合策略的经济性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coinciding with the release of the first Chinese domestic human papillomavirus (HPV) vaccine Cecolin in 2019, and the substantial advancements in cervical cancer screening technology, we aimed to evaluate the cost-effectiveness of the combined strategies of cervical cancer screening programmes and universal vaccination of girls (aged 9-14 years) with Cecolin in China. METHODS: We did a cost-effectiveness analysis in China, in which we developed a Markov model of cervical cancer to evaluate the incremental cost-effectiveness ratios of 61 intervention strategies, including a combination of various screening methods at different frequencies with and without vaccination, and also vaccination alone, from a health-care system perspective. We did univariate and probabilistic sensitivity analyses to assess the robustness of the model's findings. FINDINGS: Compared with no intervention, various combined screening and vaccination strategies would incur an additional cost of US$6 157 000-22 146 000 and result in 691-970 quality-adjusted life-years (QALYs) gained in a designated cohort of 100 000 girls aged 9-14 years over a lifetime. With a willingness-to-pay threshold of three times the Chinese per-capita gross domestic product (GDP), careHPV screening (a rapid HPV test) once every 5 years with vaccination would be the most cost-effective strategy with an incremental cost-effectiveness ratio of $21 799 per QALY compared with the lower-cost non-dominated strategy on the cost-effectiveness frontier, and the probability of it being cost-effective (44%) outperformed other strategies. Strategies that combined screening and vaccination would be more cost-effective than screening alone strategies when the vaccination cost was less than $50 for two doses, even with a lower willingness-to-pay of one times the per-capita GDP. INTERPRETATION: careHPV screening once every 5 years with vaccination is the most cost-effective strategy for cervical cancer prevention in China. A reduction in the domestic HPV vaccine price is necessary to ascertain a good economic return for the future vaccination programme. The findings provide important evidence that informs health policies for cervical cancer prevention in China. FUNDING: National Natural Science Foundation of China.
引用
- Zou Z, Fairley CK, Ong JJ, et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Glob Health. 2020. PMID: 32971056. doi:10.1016/S2214-109X(20)30277-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。